• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Previous Issues
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Egyptian Journal of Histology
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 48 (2025)
Volume Volume 47 (2024)
Volume Volume 46 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 45 (2022)
Volume Volume 44 (2021)
Volume Volume 43 (2020)
Volume Volume 42 (2019)
Volume Volume 41 (2018)
Volume Volume 40 (2017)
El-Shafei, A., Hassan, R., Hosny, S. (2023). A Comparative Histological and Immunohistochemical Study on the Possible Therapeutic Effects of Empagliflozin and platelet-rich plasma Against Cisplatin Induced Cardiotoxicity in Rats. Egyptian Journal of Histology, 46(1), 378-493. doi: 10.21608/ejh.2021.69267.1451
Asmaa Ahmed El-Shafei; Rokia Mohamad Hassan; Sara Adel Hosny. "A Comparative Histological and Immunohistochemical Study on the Possible Therapeutic Effects of Empagliflozin and platelet-rich plasma Against Cisplatin Induced Cardiotoxicity in Rats". Egyptian Journal of Histology, 46, 1, 2023, 378-493. doi: 10.21608/ejh.2021.69267.1451
El-Shafei, A., Hassan, R., Hosny, S. (2023). 'A Comparative Histological and Immunohistochemical Study on the Possible Therapeutic Effects of Empagliflozin and platelet-rich plasma Against Cisplatin Induced Cardiotoxicity in Rats', Egyptian Journal of Histology, 46(1), pp. 378-493. doi: 10.21608/ejh.2021.69267.1451
El-Shafei, A., Hassan, R., Hosny, S. A Comparative Histological and Immunohistochemical Study on the Possible Therapeutic Effects of Empagliflozin and platelet-rich plasma Against Cisplatin Induced Cardiotoxicity in Rats. Egyptian Journal of Histology, 2023; 46(1): 378-493. doi: 10.21608/ejh.2021.69267.1451

A Comparative Histological and Immunohistochemical Study on the Possible Therapeutic Effects of Empagliflozin and platelet-rich plasma Against Cisplatin Induced Cardiotoxicity in Rats

Article 34, Volume 46, Issue 1, March 2023, Page 378-493  XML PDF (2.57 MB)
Document Type: Original Article
DOI: 10.21608/ejh.2021.69267.1451
Cited by Scopus (3)
View on SCiNiTO View on SCiNiTO
Authors
Asmaa Ahmed El-Shafeiorcid 1; Rokia Mohamad Hassanorcid 2; Sara Adel Hosny email orcid 3
1Department of Medical Histology & Cell Biology, Faculty of Medicine, Cairo University, Egypt
2Histology and cell biology Department, Faculty of Medicine, Cairo University
3Histology department, faculty of medicine, cairo university
Abstract
Introduction and Objectives: Cisplatin is a highly effective chemotherapeutic drug used to treat various cancers. However, cardiotoxicity is one of the most important adverse effects of it. This study aimed to investigate and compare possible therapeutic effects of empagliflozin (EMPA) and platelet-rich plasma (PRP) on cisplatin induced cardiotoxicity in adult male albino rats.
Material and Methods: 48 adult male albino rats were classified into: Group I (control group) and Group II (Experimental group). All rats in group II were injected once with cisplatin (10 mg/kg) intraperitoneally (ip) then after 7 days they were divided into; cisplatin subgroup(II-a); rats were sacrificed on the 7th day, spontaneous recovery subgroup (II-b) was left untreated for 3 weeks, EMPA-treated subgroup (II-c) received EMPA orally daily (20 mg/kg/day) for 3 weeks and PRP-treated subgroup (II-d) received 0.5 ml/kg PRP subcutaneously (SC) twice weekly for 3 weeks. At the end of the experiment, Blood samples were collected to measure creatine kinase –MB (CK –MB), cardiac troponin I (cTnI), Superoxide Dismutase (SOD) and malondialdehyde (MDA). Cardiac muscle specimens were acquired for histological, immunohistochemical, morphometric and statistical analysis.
Results: Mean serum levels of CK-MB, cTnI & MDA was significantly increased associated with significant decrease of SOD level in cisplatin & spontaneous recovery subgroups (Subgroups II-a & II-b respectively). In addition, area percentage of collagen fibers, caspase-3 & fibronectin showed a significant increase and area percentage of Connexin 43 (Cx43) showed a significant decrease in subgroups II-a & II-b. While, EMPA-treated & PRP-treated subgroups (Subgroups II-c & II-d respectively) encountered significant amelioration in biochemical markers, histological & immunohistochemical changes induced by cisplatin with a more obvious improvement in Subgroup II-d.
Conclusion: EMPA and PRP significantly improved cisplatin-induced cardiac damage by alleviating oxidative stress, suppressing inflammation and inhibiting apoptosis; with a more pronounced improvement in response to PRP than EMPA.
Keywords
Cardiotoxicity; cisplatin; empagliflozin; PRP
Statistics
Article View: 1,041
PDF Download: 865
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.